NCT06105411 Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions
| NCT ID | NCT06105411 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peter MacCallum Cancer Centre, Australia |
| Condition | Invasive Fungal Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2023-12-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.
Eligibility Criteria
Inclusion Criteria: 1. Patient has provided written informed consent 2. Aged 18 years or older at written informed consent 3. Within 2 weeks of proven or probable or possible invasive fungal infection (IFI) diagnosis as per EORTC criteria 4. Imaging consistent with invasive pulmonary aspergillosis on CT or FDG-PET/CT with lesions at least 8mm in diameter 5. Patient is willing and able to comply with the protocol for the duration of the study including scheduled visits such as follow up Exclusion Criteria: 1. Women who are pregnant or lactating. 2. Iron infusion within one week prior to scan
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06105411 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Invasive Fungal Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06105411 currently recruiting?
Yes, NCT06105411 is actively recruiting participants. Contact the research team at Abby.Douglas@petermac.org for enrollment information.
Where is the NCT06105411 trial being conducted?
This trial is being conducted at Melbourne, Australia.
Who is sponsoring the NCT06105411 clinical trial?
NCT06105411 is sponsored by Peter MacCallum Cancer Centre, Australia. The trial plans to enroll 10 participants.